Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.39 ^USD	+3.91%		+5.29%	+35.03%

Apr. 09	Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	MT
Mar. 21	Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating	MT

Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 19, 2024 at 04:16 pm EDT

Taysha Gene Therapies, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 15.45 million compared to USD 2.5 million a year ago. Net loss was USD 111.57 million compared to USD 166.01 million a year ago.

Basic loss per share from continuing operations was USD 0.96 compared to USD 3.78 a year ago. Diluted loss per share from continuing operations was USD 0.96 compared to USD 3.78 a year ago.

Latest news about Taysha Gene Therapies, Inc.

Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	Apr. 09	MT
Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating	Mar. 21	MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	Mar. 20	MT
US Futures Flat in Wednesday's Premarket as Investors Await Fed's Interest Rate Decision	Mar. 20	MT
Top Premarket Gainers	Mar. 20	MT
Needham Adjusts Taysha Gene Therapies Price Target to $7 From $5, Maintains Buy Rating	Mar. 20	MT
Taysha Gene Therapies Surges 26% Premarket After Full-Year 2023 Results Show Narrowing Net Loss, Surging Revenue	Mar. 20	MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears	Mar. 20	DJ
Transcript : Taysha Gene Therapies, Inc., 2023 Earnings Call, Mar 19, 2024	Mar. 19
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome	Jan. 10	CI
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) added to NASDAQ Biotechnology Index	Dec. 18	CI
Taysha Gene Therapies Gets Expanded Eligibility in Canada for Early Trial of Rett Syndrome Treatment	Nov. 29	MT
Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients	Nov. 29	CI
Taysha Gene Therapies Insider Bought Shares Worth $163,000, According to a Recent SEC Filing	Nov. 20	MT
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $7 From $6, Keeps Overweight Rating	Nov. 15	MT
Taysha Gene Therapies Q3 Net Loss Widens Unexpectedly	Nov. 14	MT
Transcript : Taysha Gene Therapies, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (TSHA) TAYSHA GENE THERAPIES Posts Q3 Revenue $4.75M	Nov. 14	MT
Taysha Gene Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Taysha Gene Therapies, Inc. announced that it expects to receive $40 million in funding	Nov. 12	CI
Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees	Nov. 01	CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading	23-10-24	MT
Taysha Gene Says New Preclinical Data Reinforce TSHA-102 Potential to Address Rett Syndrome Root Cause; Shares Rise	23-10-24	MT
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy 30th Annual Congress	23-10-24	CI

Chart Taysha Gene Therapies, Inc.

Duration

Period

More charts

Company Profile

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Companyâs lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Taysha Gene Therapies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.39 USD

Average target price

6.833 USD

Spread / Average Target

+185.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TAYSHA GENE THERAPIES, INC.	+35.03%	447M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research